Profilin-2 increased expression and its altered interaction with β-actin in the striatum of 3-nitropropionic acid-induced Huntington's disease in rats

Neuroscience

Volumn 281, Issue , 2014, Pages 216-228

  Chakraborty, J ^a   Pandey, M ^a,b,c   Navneet, A K ^a,d   Appukuttan, T A ^a,e   Varghese, M ^a,f   Sreetama, S C ^a,b,g   Rajamma, U ^b   Mohanakumar, K P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b Manovikas Biomedical Research and Diagnostic Centre   (India)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Dendritic spine density; Medium spiny neurons; Striatal neurodegeneration; Suppression subtractive hybridization; Synaptic phenotype; actin polymerization

Indexed keywords

3 NITROPROPIONIC ACID; BETA ACTIN; PROFILIN; PROFILIN 2; UNCLASSIFIED DRUG; 3-NITROPROPIONIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ACTIN; CONVULSANT AGENT; NITRO DERIVATIVE; PFN2 PROTEIN, RAT; PROPIONIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ACTIN GENE; BINDING AFFINITY; BRAIN CORTEX; CELL STRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITIC SPINE; GAIT DISORDER; GENE EXPRESSION REGULATION; GENE INTERACTION; GENETIC IDENTIFICATION; HUNTINGTON CHOREA; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PFN2 GENE; PROTEIN BINDING; PROTEIN LOCALIZATION; RAT; SEQUENCE ANALYSIS; ANIMAL; CELL CULTURE TECHNIQUE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; METABOLISM; NEOSTRIATUM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ACTINS; ANIMALS; CELL CULTURE TECHNIQUES; CEREBRAL CORTEX; CONVULSANTS; DENDRITIC SPINES; DISEASE MODELS, ANIMAL; GABAERGIC NEURONS; GENE EXPRESSION; HUNTINGTON DISEASE; MALE; NEOSTRIATUM; NITRO COMPOUNDS; PROFILINS; PROPIONATES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84908145093     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.09.035     Document Type: Article

References (48)

1. Ackermann M., Matus A. Activity induced targeting of profiling and stabilization of dendritic spine morphology. Nat Neurosci 2003, 6:1194-1200.
2. Bates G. Huntingtin aggregation and toxicity in Huntington's disease. Lancet 2003, 361:1642-1644.
3. Bernstein B.W., DeWit M., Bamburg J.R. Actin disassembles reversibly during electrically induced recycling of synaptic vesicles in cultured neurons. Brain Res Mol Brain Res 1998, 53:236-251.
4. Bibb J.A., Yan Z., Svenningsson P., Snyder G.L., Pieribone V.A., Horiuchi A., Nairn A.C., Messer A., Greengard P. Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A 2000, 97:6809-6814.
5. Blum D., Gall D., Galas M.C., d'Alcantara P., Bantubungi K., Schiffmann S.N. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J Neurosci 2002, 22:9122-9133.
6. Boyl P.P., Nardo A.D., Mulle C., Sassoè-Pognetto M., Panzanelli P., Mele A., Kneussel M., Costantini V., Perlas E., Massimi M., Vara H., Giustetto M., Witke W. Profilin2 contributes to synaptic vesicle exocytosis, neuronal excitability, and novelty-seeking behavior. EMBO J 2007, 26:2991-3002.
7. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy-Willig A., Kowall N.W., Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 1995, 92:7105-7109.
8. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005, 95:1521-1540.
9. Burnett B.G., Andrews J., Ranganathan S., Fischbeck K.H., Di Prospero N.A. Expression of expanded polyglutamine targets profilin for degradation and alters actin dynamics. Neurobiol Dis 2008, 30:365-374.
10. Chakraborty J., Rajamma U., Mohanakumar K.P. A mitochondrial basis for Huntington's disease: therapeutic prospects. Mol Cell Biochem 2014, 389:277-291.
11. Chakraborty J., Singh R., Dutta D., Naskar A., Rajamma U., Mohanakumar K.P. Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's disease. CNS Neurosci Ther 2014, 20:10-19.
12. Chakraborty J., Nthenge-Ngumbau D.N., Rajamma U., Mohanakumar K.P. Melatonin protects against behavioural dysfunctions and dendritic spine damage in 3-nitropropionic acid-induced rat model of Huntington's disease. Behav Brain Res 2014, 264:91-104.
13. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997, 90:537-548.
14. Deshpande S.B., Hida H., Takei-Io N., Masuda T., Baba H., Nishino H. Involvement of nitric oxide in 3-nitropropionic acid-induced striatal toxicity in rats. Brain Res 2006, 1108:205-215.
15. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
16. Dunah A.W., Jeong H., Griffin A., Kim Y.M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
17. Ferrante R.J., Kowall N.W., Richardson E.P. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci 1991, 11:3877-3887.
18. Goehler H., Lalowski M., Stelzl U., Waelter S., Stroedicke M., Worm U., Droege A., Lindenberg K.S., Knoblich M., Haenig C., Herbst M., Suopanki J., Scherzinger E., Abraham C., Bauer B., Hasenbank R., Fritzsche A., Ludewig A.H., Büssow K., Coleman S.H., Gutekunst C.A., Landwehrmeyer B.G., Lehrach H., Wanker E.E. A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. Mol Cell 2004, 15:853-865.
19. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci 2001, 14:1492-1504.
20. La Fontaine M.A., Geddes J.W., Banks A., Butterfield D.A. 3-Nitropropionic acid-induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease. Brain Res 2000, 858:356-362.
21. Liu X., Luo X., Hu W. Studies on the epidemiology and etiology of moldy sugarcane poisoning in China. Biomed Environ Sci 1992, 5:161-177.
22. Liot G., Bossy B., Lubitz S., Kushnareva Y., Sejbuk N., Bossy-Wetzel E. Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway. Cell Death Differ 2009, 16:899-909.
23. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
24. Ludolph A.C., He F., Spencer P.S., Hammerstad J., Sabri M. 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 1991, 18:492-498.
25. Maciel E.N., Kowaltowski A.J., Schwalm F.D., Rodrigues J.M., Souza D.O., Vercesi A.E., Wajner M., Castilho R.F. Mitochondrial permeability transition in neuronal damage promoted by Ca2+ and respiratory chain complex II inhibition. J Neurochem 2004, 90:1025-1035.
26. Michaelsen K., Murk K., Zagrebelsky M., Dreznjak A., Jockusch B.M., Rothkegel M., Korte M. Fine-tuning of neuronal architecture requires two profilin isoforms. Proc Natl Acad Sci U S A 2010, 107:15780-15785.
27. Napolitano M., Centonze D., Gubellini P., Rossi S., Spiezia S., Bernardi G., Gulino A., Calabresi P. Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease. Neurobiol Dis 2004, 15:407-414.
28. Naskar A., Manivasagam T., Chakraborty J., Singh R., Thomas B., Dhanasekaran M., Mohanakumar K.P. Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J Pineal Res 2013, 55:304-312.
29. Pandey M., Varghese M., Sindhu K.M., Sreetama S., Navneet A.K., Mohanakumar K.P., Usha R. Mitochondrial NAD+-linked state 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J Neurochem 2008, 104:420-434.
30. Pandey M., Borah A., Varghese M., Barman P.K., Mohanakumar K.P., Usha R. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. Neurochem Int 2009, 55:431-437.
31. Pandey M., Mohanakumar K.P., Usha R. Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease. J Bioenerg Biomembr 2010, 42:217-226.
32. Picconi B., Passino E., Sgobio C., Bonsi P., Barone I., Ghiglieri V., Pisani A., Bernardi G., Ammassari-Teule M., Calabresi P. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis 2006, 22:143-152.
33. Puerta E., Hervias I., Barros-Miñones L., Jordan J., Ricobaraza A., Cuadrado-Tejedor M., García-Osta A., Aguirre N. Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Dis 2010, 38:237-245.
34. Rao B.S., Desiraju T., Raju T.R. Neuronal plasticity induced by self-stimulation rewarding experience in rats-a study on alteration in dendritic branching in pyramidal neurons of hippocampus and motor cortex. Brain Res 1993, 627:216-224.
35. Rao B.S.S., Govindaiah T.R., Laxmi B.L.M., Raju T.R. Subicular lesions cause dendritic atrophy in CA1 and CA3 pyramidal neurons of the rat hippocampus. Neuroscience 2001, 102:319-327.
36. Sambrook J., Russel D.W. Molecular cloning - a laboratory manual 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 3rd ed.
37. Saudou F., Finkbeiner S., Devys D., Greenberg M.E. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998, 95:55-66.
38. Selden L.A., Kinosian H.J., Estes J.E., Gershman L.C. Impact of profilin on actin-bound nucleotide exchange and actin polymerization dynamics. Biochemistry 1999, 38:2769-2778.
39. Seo H., Sonntag K.C., Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 2004, 56:319-328.
40. Shao J., Welch W.J., DiProspero N.A., Diamond M.I. Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol Cell Biol 2008, 28:5196-5208.
41. Subramaniam S., Sixt K.M., Barrow R., Snyder S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
42. Tabrizi S.J., Cleeter M.W., Xuereb J., Taanman J.W., Cooper J.M., Schapira A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 1999, 45:25-32.
43. Tang T.S., Chen X., Liu J., Bezprozvanny I. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 2007, 27:7899-7910.
44. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
45. Thomas E.A. Striatal specificity of gene expression dysregulation in Huntington's disease. J Neurosci Res 2006, 84:1151-1164.
46. Witke W. The role of profilin complexes in cell motility and other cellular processes. Trends Cell Biol 2004, 14:461-469.
47. Witke W., Podtelejnikov A.V., Di Nardo A., Sutherland J.D., Gurniak C.B., Dotti C., Mann M. In mouse brain profilin I and profilin II associate with regulators of the endocytic pathway and actin assembly. EMBO J 1998, 17:967-976.
48. Zhang W., Benson D.L. Developmentally regulated changes in cellular compartmentation and synaptic distribution of actin in hippocampal neurons. J Neurosci Res 2002, 69:427-436.